More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.37B
EPS
-3.33
P/E ratio
--
Price to sales
30.78
Dividend yield
--
Beta
1.834753
Previous close
$9.86
Today's open
$9.96
Day's range
$9.69 - $10.24
52 week range
$7.95 - $18.48
show more
CEO
John M. Leonard
Employees
377
Headquarters
Cambridge, MA
Exchange
NASDAQ Global Market
Shares outstanding
140358512
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
Intellia Therapeutics NASDAQ: NTLA presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the company awaits a U.S. regulatory decision.
MarketBeat • Nov 12, 2026

Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript
Intellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of Investor Relations & Corporate Communications John Leonard - President, CEO & Director Jing Marantz - EVP & Chief Medical Officer Maria Natale - Senior Vice President of Commercial Fred Cohen Conference Call Participants Marc Riedl Danny Cohn Joseph Thome - TD Cowen, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Alec Stranahan - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jeffrey Stith - Wells Fargo Securities, LLC, Research Division John Boyle - William Blair & Company L.L.C., Research Division Binita Shah Andy Chen - Wolfe Research, LLC Jasmine Fels - Barclays Bank PLC, Research Division Lydia Erdman Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Jade Montgomery Presentation Operator Good morning, everyone, and welcome to the Intellia Therapeutics HAE Investor Event.
Seeking Alpha • Nov 13, 2026

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor webcast today at 10:00 a.m. ET to review certain data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company's preparations for a planned commercial launch of lonvo-z in HAE.
GlobeNewsWire • Nov 12, 2026

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 at 8:30 a.m.
GlobeNewsWire • Nov 10, 2026

Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision
Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean safety profile, positioning NTLA as a transformative one-time treatment in a crowded, high-cost market. Commercial success hinges on payer acceptance, physician adoption, and pricing strategy, with initial revenues likely modest but long-term potential significant if approved.
Seeking Alpha • Nov 6, 2026

Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
Zacks Investment Research • Nov 6, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment.
GlobeNewsWire • Nov 6, 2026

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026 Completed enrollment in MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN; advanced enrollment in MAGNITUDE in ATTR-CM Existing cash resources expected to fund operations at least into 2028 and well beyond lonvo-z's anticipated commercial launch, with recent term loan facility providing additional financial flexibility CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the completion of enrollment in MAGNITUDE-2, the Phase 3 clinical trial of nex-z in patients with ATTRv-PN.
GlobeNewsWire • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Intellia Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.